Zecotek shareholders hope for Markman Hearing bump

Zecotek CEO Dr. Faouzi Zerrouk says the damages from the alleged violation of its patent by companies Saint-Gobain and Philips could be “significant”.

Shareholders of Zecotek Photonics (Zecotek Photonics Stock Quote, Chart, News: TSXV:ZMS) are no doubt hoping the company’s upcoming Markman Hearing, which it today announced will take place early in July, will do for the company what it has done for many others of late: send its share price north.

A “Markman Hearing”, aims to determine the use of relevant key words in a patent claim. The procedure has become commonplace in the U.S. Supreme Court since the 1996 case of Markman v. Westview Instruments, Inc., found that the language of a patent is a matter of law for a judge, not a jury, to decide.

Zecotek’s Markman action against defendants Saint-Gobain Corp. and Philips will be held on July 2, 2013, before U.S. district Judge Sara Lioi.

Zecotek contends that those companies infringed on its LFS scintillation crystal patent.

Zecotek was granted U.S. patent No. 7,132,060 late in 2006. The patent covers the substances and chemical formulations used to grow lutetium fine silicate scintillation or LFS crystals. LFS scintillation crystals are characterized by their combined high-light yield and ultrafast decay times and are used in medical scanning devices, high-energy science experiments, and other industrial and security applications. The lawsuit alleges that Saint-Gobain’s LYSO crystals infringe Zecotek’s patent, and that Philips infringes by using those crystals in the positron emission tomography (PET) medical scanning devices it currently sells.

CEO Dr. A.F. Zerrouk says the damages could be “significant”.

“We welcome the Markman hearing as our legal action against Saint-Gobain and Philips for infringing on our LFS scintillation crystal patent moves forward,” he said Dr. “We will continue to vigorously enforce our intellectual property rights to recover the significant damages afflicted on Zecotek and our shareholders.”

The trend of companies monetizing their intellectual property has exploded in the past few years, and Markman hearings have been seen by certain investors as key catalysts. In the U.S., companies such as Vringo (Vringo Stock Quote, Chart, News: NASDAQ:VRNG) and Parkervision (Parkervision Stock Quote, Chart, News: NASDAQ:PRKR) saw their share prices lift off after announcing Markman hearing dates against Google and Qualcomm, respectively.

At press time, shares of Zecotek were up 2.8% to $.37.

Disclosure: Zecotek is an annual sponsor of Cantech Letter.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: zms
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

27 mins ago

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

16 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

23 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

24 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

1 day ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago